Daniel Farray-Berges, MD
Hematology & Oncology · Weslaco, TXNPI 1639116288
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,106 of the $3,076 with a category attached, or 68.5%. 29 manufacturers reported payments, led by Pfizer at 40.9% of the total. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 82 payments — averaging $37.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Novartis$316
- Johnson & Johnson$232
- E.r. Squibb & Sons, L.L.C.$176
- Boston Scientific$150
- Gilead$97
- plus $847 from 23 others
Across 209 payments — averaging $1428.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Epizyme, Inc.$206K
- E.r. Squibb & Sons, L.L.C.$47K
- Pharmacyclics LLC, An Abbvie Company$18K
- Tesaro, Inc.$17K
- Merck$10K
- AstraZeneca$559
What the payments were for
- Speaking & faculty fees$85028%
- Food & beverage$2,10668%
- Education$1204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $1,258 |
| Novartis | 12 | $316 |
| Johnson & Johnson(2 entities) | 4 | $232 |
| E.r. Squibb & Sons, L.L.C. | 3 | $176 |
| Boston Scientific | 2 | $150 |
| Gilead(2 entities) | 5 | $97 |
| Astellas Pharma Global Development | 1 | $88 |
| Eisai Inc. | 4 | $88 |
| GSK | 5 | $86 |
| Bristol Myers Squibb | 3 | $72 |
| AstraZeneca | 1 | $68 |
| Seagen Inc. | 4 | $58 |
| Genentech USA, Inc. | 2 | $44 |
| Exelixis Inc. | 2 | $40 |
| ADC Therapeutics America, Inc. | 2 | $32 |
| Tempus AI, Inc | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Amgen | 1 | $23 |
| Array Biopharma Inc | 1 | $21 |
| Merck | 2 | $20 |
| Bayer | 1 | $20 |
| Geron Corporation | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Morphosys, US Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Sirtex Medical Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,076 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 77 | $1,095,770 |
| CabometyxCabozantinib S-Malate | 38 | $817,246 |
| IbrancePalbociclib | 50 | $772,847 |
| VerzenioAbemaciclib | 46 | $687,320 |
| LenvimaLenvatinib Mesylate | 25 | $573,486 |
| CalquenceAcalabrutinib Maleate | 27 | $379,155 |
| ErleadaApalutamide | 25 | $356,896 |
| Lenalidomide | 28 | $355,560 |
| PromactaEltrombopag Olamine | 50 | $346,002 |
| LonsurfTrifluridine/Tipiracil Hcl | 15 | $283,180 |
| TasignaNilotinib Hcl | 13 | $260,360 |
| ScemblixAsciminib Hydrochloride | 12 | $240,178 |
| BrukinsaZanubrutinib | 14 | $195,279 |
| XtandiEnzalutamide | 15 | $94,515 |
| Abiraterone Acetate | 35 | $45,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $72 | $1,095,77077 claims |
| NovartisPromacta, Tasigna, Scemblix | $316 | $846,54075 claims |
| Exelixis Inc.Cabometyx | $40 | $817,24638 claims |
| PfizerIbrance, Eliquis | $1,258 | $787,47573 claims |
| Eisai Inc.Lenvima | $88 | $573,48625 claims |
| AstraZenecaCalquence | $68 | $379,15527 claims |
| Johnson & JohnsonErleada | $232 | $356,89625 claims |
| Astellas Pharma US IncXtandi | $14 | $94,51515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Weslaco
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.